Last checked at 
11 Jul 2019 11:21
Syncona Limited
Issue of shares pursuant to Long Term Incentive Plan and PDMR dealings
11 July 2019
Syncona Limited (the "Company") today announces that a total of 1,583,138 new ordinary shares will be issued in satisfaction of realisations under the Company's Long Term Incentive Plan. The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the Long Term Incentive Plan, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 10 July 2019, £2.17.
In accordance with the rules of the Long Term Incentive Plan, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.
The issue of shares include the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:
Name | SIML Title | No. of shares to be issued |
Martin Murphy | Chief Executive Officer | 508,879 |
Chris Hollowood | Chief Investment Officer | 286,996 |
John Bradshaw | Chief Financial Officer | 101,143 |
Application has been made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 17 July 2019.
Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.
[ENDS]
Enquiries
Syncona Ltd
Siobhan Weaver / Annabel Clay
Tel : +44 (0) 20 3981 7940
FTI Consulting
Brett Pollard / Natalie Garland-Collins
Tel: +44 (0) 20 3727 1000
Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com
About Syncona
Syncona is a leading FTSE250 healthcare company focused on founding, building and funding global leaders in life science. Our vision is to deliver transformational treatments to patients in truly innovative areas of healthcare while generating superior returns for shareholders.
We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses.
We take a long-term view, underpinned by a deep pool of capital, and are established leaders in gene and cell therapy. We focus on delivering dramatic efficacy for patients in areas of high unmet need.
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | Martin Murphy | ||||
b) | Position / status | Chief Executive Officer, SIML | ||||
c) | Initial notification / amendment | Initial Notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares GG00B8P59C08 | ||||
b) | Nature of the transaction | Issue of shares pursuant to the Syncona Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price |
N/A | ||||
e) | Date of the transaction | 11 July 2019 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
g) | Currency | GBP - British Pound | ||||
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | Chris Hollowood | ||||
b) | Position / status | Chief Investment Officer, SIML | ||||
c) | Initial notification / amendment | Initial Notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares GG00B8P59C08 | ||||
b) | Nature of the transaction | Issue of shares pursuant to the Syncona Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price |
N/A | ||||
e) | Date of the transaction | 11 July 2019 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
g) | Currency | GBP - British Pound | ||||
1. | Details of PDMR / person closely associated with them ("PCA") | |||||
a) | Name | John Bradshaw | ||||
b) | Position / status | Chief Financial Officer, SIML | ||||
c) | Initial notification / amendment | Initial Notification | ||||
2. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument | Ordinary shares GG00B8P59C08 | ||||
b) | Nature of the transaction | Issue of shares pursuant to the Syncona Long Term Incentive Plan | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information Aggregated volume Price |
N/A | ||||
e) | Date of the transaction | 11 July 2019 | ||||
f) | Place of the transaction | Outside a trading venue | ||||
g) | Currency | GBP - British Pound | ||||